Skip to main content
. 2022 Dec 13;32(12):1500–1508. doi: 10.1089/thy.2022.0282

Table 3.

Patient Characteristics and Outcomes of the Recurrence-Free Survival Cohort and by Molecular Risk Group

  Total (n = 92) MRG
p
Low (n = 18) Intermediate (n = 63) High (n = 11)
Mean age (SD), year 52.3 (17.7) 52.5 (19.1) 49.3 (16.9) 69.0 (9.3) 0.002
Female 56 (60.9%) 11 (61.1%) 38 (60.3%) 7 (63.6%) 0.98
Median nodule size (range), cm 2.0 (0.6–11.1) 2.5 (1.4–6.1) 1.7 (0.6–6.7) 4.1 (1.2–11.1) <0.001
TI-RADS score         0.002
 3 16 (17.4%) 7 (38.9%) 7 (11.1%) 2 (18.2%)  
 4 40 (43.5%) 9 (50.0%) 31 (49.2%) 0 (0.0%)  
 5 32 (34.8%) 2 (11.1%) 22 (34.9%) 8 (72.7%)  
 NA 4 (4.4%) 0 (0.0%) 3 (4.8%) 1 (9.1%)  
Total thyroidectomy 67 (72.8%) 10 (55.6%) 50 (79.4%) 7 (62.6%) 0.10
Central node dissection
 Prophylactic 19 (20.7%) 4 (22.2%) 13 (20.6%) 2 (18.2%) 1.00
 Therapeutic 12 (13.0%) 1 (5.6%) 8 (12.7%) 3 (27.3%) 0.27
Central nodal disease 18 (19.5%) 1 (5.6%) 14 (22.2%) 3 (27.3%) 0.20
Lateral nodal disease 4 (4.4%) 0 (0.0%) 3 (4.8%) 1 (9.1%) 0.53
Extrathyroidal extension          
 Microscopic 19 (20.7%) 1 (5.6%) 13 (20.6%) 5 (45.5%) 0.04
 Gross 2 (2.2%) 0 (0.0%) 0 (0.0%) 2 (18.2%) 0.01
ATA risk category         < 0.001
 Low 57 (62.0%) 16 (88.9%) 40 (63.5%) 1 (9.1%)  
 Intermediate 24 (26.1%) 2 (11.1%) 19 (30.2%) 3 (27.3%)  
 High 6 (6.5%) 0 (0.0%) 3 (4.8%) 3 (27.3%)  
 NA 5 (5.4%) 0 (0.0%) 1 (1.6%) 4 (36.4%)  
RAI 31 (33.7%) 4 (22.2%) 19 (30.2%) 8 (72.7%) 0.01
Recurrence 12 (13.0%) 0 (0.0%) 6 (9.5%) 6 (54.6%) < 0.001
Death
 All-cause 4 (4.4%) 1 (5.6%) 1 (1.6%) 2 (18.2%) 0.05
 Disease specific 1 (1.1%) 0 (0.0%) 0 (0.0%) 1 (9.1%) 0.12
Mean follow-up (range), months 51.2 (<1–470) 51.3 (30–83) 46.3 (4–315) 78.6 (<1–470) 0.29

ATA, American Thyroid Association; NA, not applicable; RAI, radioactive iodine; SD, standard deviation; TI-RADS, Thyroid Imaging, Reporting and Data System.